Influence of loxoprofen use on recovery from naturally acquired upper respiratory tract infections: A randomized controlled trial

Masashi Goto, Takashi Kawamura, Takuro Shimbo, Osamu Takahashi, Masahiko Ando, Koichi Miyaki, Takahiko Nohara, Hidetsuna Watanabe, Isamu Suzuki, Mitsuru Aono, Kunihiko Matsui, Kaoru Shimokata, Tsuguya Fukui, Shuichi Saeki, Jun Nagano, Shuji Miyake, Isao Ohsawa, Hirokazu Sakamoto, Norihiko Iida, Shigeki MabuchiHideki Nomura, Yoshikazu Tasaka, Yoshimitsu Suzuki, Mitsuhiro Kamei, Kazuhiko Kikawa, Hidetoshi Matsubara, Yuko Takahashi, Yukihiro Yamaguchi, Takuji Yamada, Yohei Fukumoto

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: To investigate whether loxoprofen, one of the nonsteroidal anti-inflammatory drugs, prolongs the recovery process of naturally acquired upper respiratory tract infections (URTIs) in the clinical setting. Methods: A double-blind, randomized, placebo-controlled trial was conducted in 23 outpatient facilities in Japan. Patients aged 18 through 65 years suffering from URTIs were randomly assigned to receive loxoprofen or its placebo. The primary outcome was duration of illness in days. Results: A total of 174 patients were available for the analyses. Duration of illness was 8.94 ± 3.20 days in the loxoprofen group compared to 8.39 ± 3.39 days in the placebo group (P=.19). The number of days with limited daily activities was fewer in the loxoprofen group than in the placebo group (2.12 ± 2.05 days vs. 2.68 ± 2.54 days, P=.17). Although severe symptoms were less frequent on days 1, 2, and 3 in the loxoprofen group (27%, 33%, and 29%, respectively) than in the placebo group (32%, 39%, and 37%, respectively), symptoms were more frequent on days 6 through 12 in the loxoprofen group (difference, 5-13%). Adverse events were more common in the loxoprofen group (9.5% vs. 1.1%, P=.051). Conclusion: Loxoprofen did not significantly modify the recovery process of URTIs except for a slight tendency to delay.

Original languageEnglish
Pages (from-to)1179-1185
Number of pages7
JournalInternal Medicine
Volume46
Issue number15
DOIs
Publication statusPublished - Aug 2 2007

Fingerprint

Respiratory Tract Infections
Randomized Controlled Trials
Placebos
Sick Leave
loxoprofen
Double-Blind Method
Japan
Anti-Inflammatory Agents
Outpatients
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Influence of loxoprofen use on recovery from naturally acquired upper respiratory tract infections : A randomized controlled trial. / Goto, Masashi; Kawamura, Takashi; Shimbo, Takuro; Takahashi, Osamu; Ando, Masahiko; Miyaki, Koichi; Nohara, Takahiko; Watanabe, Hidetsuna; Suzuki, Isamu; Aono, Mitsuru; Matsui, Kunihiko; Shimokata, Kaoru; Fukui, Tsuguya; Saeki, Shuichi; Nagano, Jun; Miyake, Shuji; Ohsawa, Isao; Sakamoto, Hirokazu; Iida, Norihiko; Mabuchi, Shigeki; Nomura, Hideki; Tasaka, Yoshikazu; Suzuki, Yoshimitsu; Kamei, Mitsuhiro; Kikawa, Kazuhiko; Matsubara, Hidetoshi; Takahashi, Yuko; Yamaguchi, Yukihiro; Yamada, Takuji; Fukumoto, Yohei.

In: Internal Medicine, Vol. 46, No. 15, 02.08.2007, p. 1179-1185.

Research output: Contribution to journalArticle

Goto, M, Kawamura, T, Shimbo, T, Takahashi, O, Ando, M, Miyaki, K, Nohara, T, Watanabe, H, Suzuki, I, Aono, M, Matsui, K, Shimokata, K, Fukui, T, Saeki, S, Nagano, J, Miyake, S, Ohsawa, I, Sakamoto, H, Iida, N, Mabuchi, S, Nomura, H, Tasaka, Y, Suzuki, Y, Kamei, M, Kikawa, K, Matsubara, H, Takahashi, Y, Yamaguchi, Y, Yamada, T & Fukumoto, Y 2007, 'Influence of loxoprofen use on recovery from naturally acquired upper respiratory tract infections: A randomized controlled trial', Internal Medicine, vol. 46, no. 15, pp. 1179-1185. https://doi.org/10.2169/internalmedicine.46.6334
Goto, Masashi ; Kawamura, Takashi ; Shimbo, Takuro ; Takahashi, Osamu ; Ando, Masahiko ; Miyaki, Koichi ; Nohara, Takahiko ; Watanabe, Hidetsuna ; Suzuki, Isamu ; Aono, Mitsuru ; Matsui, Kunihiko ; Shimokata, Kaoru ; Fukui, Tsuguya ; Saeki, Shuichi ; Nagano, Jun ; Miyake, Shuji ; Ohsawa, Isao ; Sakamoto, Hirokazu ; Iida, Norihiko ; Mabuchi, Shigeki ; Nomura, Hideki ; Tasaka, Yoshikazu ; Suzuki, Yoshimitsu ; Kamei, Mitsuhiro ; Kikawa, Kazuhiko ; Matsubara, Hidetoshi ; Takahashi, Yuko ; Yamaguchi, Yukihiro ; Yamada, Takuji ; Fukumoto, Yohei. / Influence of loxoprofen use on recovery from naturally acquired upper respiratory tract infections : A randomized controlled trial. In: Internal Medicine. 2007 ; Vol. 46, No. 15. pp. 1179-1185.
@article{9708cccc0a3d4b82a5233dde9a839f03,
title = "Influence of loxoprofen use on recovery from naturally acquired upper respiratory tract infections: A randomized controlled trial",
abstract = "Objective: To investigate whether loxoprofen, one of the nonsteroidal anti-inflammatory drugs, prolongs the recovery process of naturally acquired upper respiratory tract infections (URTIs) in the clinical setting. Methods: A double-blind, randomized, placebo-controlled trial was conducted in 23 outpatient facilities in Japan. Patients aged 18 through 65 years suffering from URTIs were randomly assigned to receive loxoprofen or its placebo. The primary outcome was duration of illness in days. Results: A total of 174 patients were available for the analyses. Duration of illness was 8.94 ± 3.20 days in the loxoprofen group compared to 8.39 ± 3.39 days in the placebo group (P=.19). The number of days with limited daily activities was fewer in the loxoprofen group than in the placebo group (2.12 ± 2.05 days vs. 2.68 ± 2.54 days, P=.17). Although severe symptoms were less frequent on days 1, 2, and 3 in the loxoprofen group (27{\%}, 33{\%}, and 29{\%}, respectively) than in the placebo group (32{\%}, 39{\%}, and 37{\%}, respectively), symptoms were more frequent on days 6 through 12 in the loxoprofen group (difference, 5-13{\%}). Adverse events were more common in the loxoprofen group (9.5{\%} vs. 1.1{\%}, P=.051). Conclusion: Loxoprofen did not significantly modify the recovery process of URTIs except for a slight tendency to delay.",
author = "Masashi Goto and Takashi Kawamura and Takuro Shimbo and Osamu Takahashi and Masahiko Ando and Koichi Miyaki and Takahiko Nohara and Hidetsuna Watanabe and Isamu Suzuki and Mitsuru Aono and Kunihiko Matsui and Kaoru Shimokata and Tsuguya Fukui and Shuichi Saeki and Jun Nagano and Shuji Miyake and Isao Ohsawa and Hirokazu Sakamoto and Norihiko Iida and Shigeki Mabuchi and Hideki Nomura and Yoshikazu Tasaka and Yoshimitsu Suzuki and Mitsuhiro Kamei and Kazuhiko Kikawa and Hidetoshi Matsubara and Yuko Takahashi and Yukihiro Yamaguchi and Takuji Yamada and Yohei Fukumoto",
year = "2007",
month = "8",
day = "2",
doi = "10.2169/internalmedicine.46.6334",
language = "English",
volume = "46",
pages = "1179--1185",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "15",

}

TY - JOUR

T1 - Influence of loxoprofen use on recovery from naturally acquired upper respiratory tract infections

T2 - A randomized controlled trial

AU - Goto, Masashi

AU - Kawamura, Takashi

AU - Shimbo, Takuro

AU - Takahashi, Osamu

AU - Ando, Masahiko

AU - Miyaki, Koichi

AU - Nohara, Takahiko

AU - Watanabe, Hidetsuna

AU - Suzuki, Isamu

AU - Aono, Mitsuru

AU - Matsui, Kunihiko

AU - Shimokata, Kaoru

AU - Fukui, Tsuguya

AU - Saeki, Shuichi

AU - Nagano, Jun

AU - Miyake, Shuji

AU - Ohsawa, Isao

AU - Sakamoto, Hirokazu

AU - Iida, Norihiko

AU - Mabuchi, Shigeki

AU - Nomura, Hideki

AU - Tasaka, Yoshikazu

AU - Suzuki, Yoshimitsu

AU - Kamei, Mitsuhiro

AU - Kikawa, Kazuhiko

AU - Matsubara, Hidetoshi

AU - Takahashi, Yuko

AU - Yamaguchi, Yukihiro

AU - Yamada, Takuji

AU - Fukumoto, Yohei

PY - 2007/8/2

Y1 - 2007/8/2

N2 - Objective: To investigate whether loxoprofen, one of the nonsteroidal anti-inflammatory drugs, prolongs the recovery process of naturally acquired upper respiratory tract infections (URTIs) in the clinical setting. Methods: A double-blind, randomized, placebo-controlled trial was conducted in 23 outpatient facilities in Japan. Patients aged 18 through 65 years suffering from URTIs were randomly assigned to receive loxoprofen or its placebo. The primary outcome was duration of illness in days. Results: A total of 174 patients were available for the analyses. Duration of illness was 8.94 ± 3.20 days in the loxoprofen group compared to 8.39 ± 3.39 days in the placebo group (P=.19). The number of days with limited daily activities was fewer in the loxoprofen group than in the placebo group (2.12 ± 2.05 days vs. 2.68 ± 2.54 days, P=.17). Although severe symptoms were less frequent on days 1, 2, and 3 in the loxoprofen group (27%, 33%, and 29%, respectively) than in the placebo group (32%, 39%, and 37%, respectively), symptoms were more frequent on days 6 through 12 in the loxoprofen group (difference, 5-13%). Adverse events were more common in the loxoprofen group (9.5% vs. 1.1%, P=.051). Conclusion: Loxoprofen did not significantly modify the recovery process of URTIs except for a slight tendency to delay.

AB - Objective: To investigate whether loxoprofen, one of the nonsteroidal anti-inflammatory drugs, prolongs the recovery process of naturally acquired upper respiratory tract infections (URTIs) in the clinical setting. Methods: A double-blind, randomized, placebo-controlled trial was conducted in 23 outpatient facilities in Japan. Patients aged 18 through 65 years suffering from URTIs were randomly assigned to receive loxoprofen or its placebo. The primary outcome was duration of illness in days. Results: A total of 174 patients were available for the analyses. Duration of illness was 8.94 ± 3.20 days in the loxoprofen group compared to 8.39 ± 3.39 days in the placebo group (P=.19). The number of days with limited daily activities was fewer in the loxoprofen group than in the placebo group (2.12 ± 2.05 days vs. 2.68 ± 2.54 days, P=.17). Although severe symptoms were less frequent on days 1, 2, and 3 in the loxoprofen group (27%, 33%, and 29%, respectively) than in the placebo group (32%, 39%, and 37%, respectively), symptoms were more frequent on days 6 through 12 in the loxoprofen group (difference, 5-13%). Adverse events were more common in the loxoprofen group (9.5% vs. 1.1%, P=.051). Conclusion: Loxoprofen did not significantly modify the recovery process of URTIs except for a slight tendency to delay.

UR - http://www.scopus.com/inward/record.url?scp=34548062906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548062906&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.46.6334

DO - 10.2169/internalmedicine.46.6334

M3 - Article

C2 - 17675766

AN - SCOPUS:34548062906

VL - 46

SP - 1179

EP - 1185

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 15

ER -